{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T16:26:10Z","timestamp":1764433570378,"version":"3.40.5"},"reference-count":16,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Purpose<\/jats:title>\n<jats:p>We evaluated the IOP-lowering efficacy and safety of latanoprostene bunod (LBN) ophthalmic solution 0.024% (Vyzulta\u00ae), the first topical nitric oxide-donating prostaglandin analog (PGA), in clinical practice.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Materials and methods<\/jats:title>\n<jats:p>A retrospective medical chart review from July 2021 to July 2023 of patients with open-angle glaucoma receiving LBN with at least 1 year follow\u2013up was conducted. All included patients received LBN 0.024% as a replacement for a PGA, with examinations at 1-, 3-, 6-and 12-months follow-up. Main outcome measures were IOP, retinal nerve fiber layer thickness, visual fields before\/after LBN use and adverse effects. Subgroup analysis with glaucoma types and PGA use were performed for additional IOP reduction after LBN use.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Among 78 included patients, 47 patients (81 eyes), 60% with open-angle glaucoma (OAG) remained on LBN throughout 12-month follow-up. Baseline IOP was 18.2\u00b14.2 mm Hg, and Prostaglandin analog (PGA)-IOP was 14.4 \u00b1 3.0 mm Hg (21% mean IOP reduction). After switched to LBN, mean additional IOP reduction was 1.0 mm Hg at month 1, and the greatest reduction was 1.6 mm Hg (8.8% additional mean IOP reduction) at month 12 (P&lt;0.0001). Subgroup analysis (NTG, 73%) showed that mean additional IOP reduction at month 12 was 1.3\u00b12.0 mm Hg in NTG group and 2.1\u00b13.2 mm Hg in POAG group (7.7% vs. 8.7% additional IOP reduction rates, P = 0.23). Subgroup analysis of PGA use at month 12 was 1.8\u00b12.3 mm Hg in tafluoprost group and 0.5\u00b11.7 mm Hg in travoprost group (9.5% vs.2.6% additional IOP reduction rates, P = 0.02). Tolerable ocular adverse effects included irritation (n = 16, 19.8%), mild conjunctival hyperemia (n = 11, 13.6%), dark circles (n = 4, 4.9%) and blurred vision (n = 2, 2.5%). There were no significant visual field and retinal nerve fiber layer thickness changes after 12 months of treatment with LBN 0.024%.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Although high intolerable adverse effects including conjunctival hyperemia and eye irritation happened in the first month, remaining sixty percent of patients exhibited statistically significant additional IOP reductions in the replacement of other PGAs during 12 months of clinical use of LBN 0.024%.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0307132","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T19:14:01Z","timestamp":1724354041000},"page":"e0307132","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["One-year experience with latanoprostene bunod ophthalmic solution 0.024% in clinical practice: A retrospective observational study"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7339-3365","authenticated-orcid":true,"given":"Chun-Mei","family":"Hsueh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Hsin","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jou-Chen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si-Huei","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsung-Jen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9069-061X","authenticated-orcid":true,"given":"Siao-Pei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"issue":"1","key":"pone.0307132.ref001","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/APO.0000000000000177","article-title":"Update on the Prevalence, Etiology, Diagnosis, and Monitoring of Normal-Tension Glaucoma","volume":"5","author":"KE Kim","year":"2016","journal-title":"Asia-Pacific journal of ophthalmology (Philadelphia, Pa)"},{"issue":"1","key":"pone.0307132.ref002","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/archopht.121.1.48","article-title":"Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial","volume":"121","author":"MC Leske","year":"2003","journal-title":"Archives of ophthalmology (Chicago, Ill: 1960)"},{"issue":"1","key":"pone.0307132.ref003","doi-asserted-by":"crossref","first-page":"P41","DOI":"10.1016\/j.ophtha.2015.10.053","article-title":"Primary Open-Angle Glaucoma Preferred Practice Pattern(\u00ae) Guidelines","volume":"123","author":"BE Prum","year":"2016","journal-title":"Ophthalmology"},{"issue":"4","key":"pone.0307132.ref004","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/14656566.2017.1293654","article-title":"Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension","volume":"18","author":"PL Kaufman","year":"2017","journal-title":"Expert opinion on pharmacotherapy"},{"issue":"5","key":"pone.0307132.ref005","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ophtha.2016.01.019","article-title":"Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study","volume":"123","author":"RN Weinreb","year":"2016","journal-title":"Ophthalmology"},{"key":"pone.0307132.ref006","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ajo.2016.05.012","article-title":"Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study","volume":"168","author":"FA Medeiros","year":"2016","journal-title":"American journal of ophthalmology"},{"issue":"1","key":"pone.0307132.ref007","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/IJG.0000000000000831","article-title":"Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings","volume":"27","author":"RN Weinreb","year":"2018","journal-title":"Journal of glaucoma"},{"issue":"9","key":"pone.0307132.ref008","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1007\/s12325-016-0385-7","article-title":"Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study","volume":"33","author":"K Kawase","year":"2016","journal-title":"Advances in therapy"},{"issue":"5","key":"pone.0307132.ref009","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1136\/bjophthalmol-2020-317262","article-title":"Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis","volume":"106","author":"P Harasymowycz","year":"2022","journal-title":"The British journal of ophthalmology"},{"issue":"4","key":"pone.0307132.ref010","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s40123-020-00307-0","article-title":"Retrospective Chart Review on Real-World Use of Latanoprostene Bunod 0.024% in Treatment-Na\u00efve Patients with Open-Angle Glaucoma","volume":"9","author":"CO Okeke","year":"2020","journal-title":"Ophthalmology and therapy"},{"issue":"6","key":"pone.0307132.ref011","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1136\/bjophthalmol-2014-305908","article-title":"A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study","volume":"99","author":"RN Weinreb","year":"2015","journal-title":"The British journal of ophthalmology"},{"key":"pone.0307132.ref012","first-page":"11","article-title":"Latanoprostene Bunod 0.024% in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: A Meta-Analysis","author":"TC Lo","year":"2022","journal-title":"Journal of clinical medicine"},{"issue":"1","key":"pone.0307132.ref013","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/s12886-022-02553-1","article-title":"Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China","volume":"22","author":"X Sun","year":"2022","journal-title":"BMC ophthalmology"},{"issue":"1","key":"pone.0307132.ref014","doi-asserted-by":"crossref","first-page":"108","DOI":"10.18240\/ijo.2023.01.16","article-title":"Safety profile of 0.0015% tafluprost eye drops in China: a post-marketing observational study","volume":"16","author":"XL Chen","year":"2023","journal-title":"International journal of ophthalmology"},{"issue":"4","key":"pone.0307132.ref015","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.curtheres.2009.08.006","article-title":"Effects of travoprost in the treatment of open-angle glaucoma or ocular hypertension: A systematic review and meta-analysis","volume":"70","author":"JW Cheng","year":"2009","journal-title":"Current therapeutic research, clinical and experimental"},{"issue":"11","key":"pone.0307132.ref016","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/eye.2012.195","article-title":"Adverse periocular reactions to five types of prostaglandin analogs","volume":"26","author":"K Inoue","year":"2012","journal-title":"Eye"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0307132","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T19:14:17Z","timestamp":1724354057000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0307132"}},"subtitle":[],"editor":[{"given":"Natasha","family":"Gautam","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":16,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0307132","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2024,8,22]]}}}